Marché mondial de l’infarctus aigu du myocarde – Tendances et prévisions du secteur jusqu’en 2031

Analyse et taille du marché du traitement de l'infarctus aigu du myocarde

Selon la National Library of Medicine des États-Unis, environ 70 % des cas mortels d’IAM sont liés à des blocages causés par des plaques d’athérosclérose. L’athérosclérose étant la principale cause d’IAM, les efforts de prévention de la maladie se concentrent souvent sur la réduction des facteurs de risque qui y sont associés. Les facteurs de risque modifiables contribuent à 90 % des cas d’IAM chez les hommes et à 94 % chez les femmes. Ces facteurs, qui peuvent être modifiés ou contrôlés, comprennent le tabagisme, le manque d’activité physique, l’hypertension artérielle, l’obésité, des taux élevés de cholestérol (en particulier de LDL) et des taux élevés de triglycérides. En revanche, l’âge, le sexe et les antécédents familiaux sont des facteurs de risque non modifiables de l’athérosclérose et de l’IAM.

Français La taille du marché mondial de l'infarctus aigu du myocarde était évaluée à 2,05 milliards USD en 2023 et devrait atteindre 3,37 milliards USD d'ici 2031, avec un TCAC de 6,4 % au cours de la période de prévision de 2024 à 2031. En plus des informations sur les scénarios de marché tels que la valeur marchande, le taux de croissance, la segmentation, la couverture géographique et les principaux acteurs, les rapports de marché organisés par Data Bridge Market Research comprennent également une analyse approfondie des experts, l'épidémiologie des patients, l'analyse du pipeline, l'analyse des prix et le cadre réglementaire.

Portée du rapport et segmentation du marché       

Market Definition

Post-acute myocardial infarction (AMI), commonly known as a heart attack, refers to the period following the acute phase of a heart attack. The post-acute phase is characterized by ongoing recovery, rehabilitation, and managing the patient's condition to prevent future cardiac events. This phase typically involves lifestyle modifications, such as dietary changes, exercise programs, and smoking cessation, as well as medication management to control risk factors such as hypertension, hyperlipidemia, and diabetes.                                     

Post Acute Myocardial Infarction Market Dynamics

Drivers

• Increasing Prevalence of Cardiovascular Diseases

The prevalence of cardiovascular diseases, including acute myocardial infarction (AMI), is on the rise globally. Sedentary lifestyles, unhealthy dietary habits, and an aging population are contributing factors to the increasing incidence of these diseases. Sedentary lifestyles, characterized by low levels of physical activity, are linked to obesity, hypertension, and other risk factors for cardiovascular diseases. As the population ages, the risk of developing cardiovascular diseases increases, further driving the market growth.     

• Advancements in Treatment Options

Technological advancements and innovations in treatment options for AMI have significantly improved patient outcomes and reduced the risk of complications. One such advancement is the development of drug-eluting stents, which help prevent restenosis (the re-narrowing of arteries) after angioplasty. Minimally invasive procedures, such as percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG), have also become more refined, leading to shorter recovery times and improved patient outcomes. Personalized medicine, which involves tailoring treatment plans based on individual patient characteristics, has emerged as a promising approach to treating AMI. These advancements in treatment options are driving market growth.

Opportunities

• Rising Healthcare Expenditure

With growing economies and aging populations, there is a greater focus on improving healthcare infrastructure and access to medical services. This is fueling the need for sophisticated treatments and technologies for conditions such as AMI. Moreover, the rise in disposable incomes and the expansion of the middle class in numerous developing nations are boosting healthcare expenditure. As a result, there is a growing market for AMI treatments in these regions, presenting opportunities for pharmaceutical companies, medical device manufacturers, and healthcare providers to expand their presence and offerings.              

• Integration of Digital Health Solutions

Integrating digital health solutions, such as telemedicine, remote monitoring, and mobile health apps, is revolutionizing the management of AMI. These digital solutions enable healthcare providers to monitor patients with AMI more efficiently and cost-effectively, facilitating the delivery of timely and personalized care. Telemedicine, in particular, has emerged as a valuable tool for remote consultation and monitoring patients with AMI, reducing the need for in-person visits and improving patient outcomes. Furthermore, using mobile health apps for self-management and education has empowered patients to take a more active role in their healthcare. Overall, the integration of digital health solutions enhances patient care and management of AMI while creating new opportunities for innovation and growth in the market.

Restraints/Challenges

• Risk of Complications

Despite advancements in treatment options, treatments for acute myocardial infarction (AMI) carry a risk of complications that can deter patients from seeking treatment. These complications can include bleeding, infection, and cardiac arrhythmias, among others. Bleeding may occur as a side effect of anticoagulant medications used to prevent blood clotting, a common complication of AMI. Infection can occur due to the invasive nature of some treatments, such as angioplasty or coronary artery bypass grafting (CABG). Cardiac arrhythmias, or irregular heartbeats, can occur due to damage to the heart muscle during AMI. These complications can be serious and require additional medical intervention, which can be daunting for patients and may lead them to avoid or delay seeking treatment for AMI, which can hinder the market growth. 

• Stringent Regulatory Requirements

Stringent regulatory requirements are implemented to guarantee the safety, effectiveness, and quality of new treatments and devices. Companies must conduct extensive clinical trials to demonstrate the safety and efficacy of their products, which can be time-consuming and costly. In addition, regulatory agencies may require additional data or studies before approving a new treatment or device, further delaying market entry. These regulations for approving new treatments and devices for AMI can pose a challenge for companies in the market.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In November 2022, Abiomed, a leading provider of cardiovascular technologies, agreed to be acquired by Johnson & Johnson for USD 16.6 billion. Upon completing the transaction, Abiomed will enhance Johnson & Johnson MedTech's position as a leading cardiovascular innovator and will continue to operate as a separate business entity. This acquisition aims to advance the standard of care for heart failure, a serious disease, and improve patient outcomes
• In August 2022, late-breaking research presented in a Hot Line session revealed that administering Asundexian 50 mg to post-myocardial infarction patients inhibited factor XIa by more than 90% without a significant increase in bleeding. Asundexian and other factor XIa inhibitors could be promising new therapies for reducing ischaemic events without significantly increasing bleeding in patients following myocardial infarction and in other clinical settings where vascular thrombosis or thromboembolism are concerns

Post Acute Myocardial Infarction Market Scope

The market is segmented on the basis of drug class, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drug Class

• Antiplatelet Therapy
• Beta Blockers

End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Post Acute Myocardial Infarction Market Regional Analysis/Insights

The market is analyzed and market size insights and trends are provided by country, drug class, distribution channel, and end-user as referenced above.

The countries covered in the market are U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa, Brazil, Argentina, and Rest of South America.

North America is expected to dominate the market due to high prevalence of myocardial infarction, driving the demand for effective treatment options. In addition, North America boasts significant advancements in treatment technologies, including cutting-edge medical devices and pharmaceuticals, which further propel market growth. Moreover, the presence of well-established healthcare infrastructure and the adoption of advanced healthcare practices in the region contribute to its dominant position in the market.

Asia-Pacific is expected to witness significant growth during the forecast period due to the market being dominated by a vulnerable aging population that is particularly susceptible to cardiovascular disorders. This demographic trend has contributed significantly to the region's dominance in the market.

La section pays du rapport fournit également des facteurs d'impact sur les marchés individuels et des changements de réglementation sur le marché national qui ont un impact sur les tendances actuelles et futures du marché. Des points de données tels que l'analyse de la chaîne de valeur en aval et en amont, les tendances techniques et l'analyse des cinq forces de Porter, les études de cas sont quelques-uns des indicateurs utilisés pour prévoir le scénario de marché pour les différents pays. En outre, la présence et la disponibilité des marques mondiales et les défis auxquels elles sont confrontées en raison de la concurrence importante ou rare des marques locales et nationales, l'impact des tarifs nationaux et les routes commerciales sont pris en compte tout en fournissant une analyse prévisionnelle des données nationales.

Croissance de la base installée des infrastructures de santé et pénétration des nouvelles technologies

Le marché vous fournit également une analyse détaillée du marché pour chaque pays, la croissance des dépenses de santé pour les biens d'équipement, la base installée de différents types de produits pour le marché, l'impact de la technologie à l'aide de courbes de vie et les changements dans les scénarios réglementaires des soins de santé et leur impact sur le marché. Les données sont disponibles pour la période historique 2011-2021.

Analyse du paysage concurrentiel et des parts de marché du traitement de l'infarctus aigu du myocarde

Le paysage concurrentiel du marché fournit des détails par concurrent. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements dans la recherche et le développement, les nouvelles initiatives du marché, la présence mondiale, les sites et installations de production, les capacités de production, les forces et les faiblesses de l'entreprise, le lancement du produit, la largeur et l'étendue du produit, la domination des applications. Les points de données ci-dessus fournis ne concernent que l'orientation des entreprises par rapport au marché.

Certains des principaux acteurs opérant sur le marché sont :

• F. Hoffmann-La Roche SA (Suisse)
• Fresenius Kabi AG (Allemagne)
• Bayer AG (Allemagne)
• Sun Pharmaceutical Industries Ltd (Inde)
• Novartis SA (Suisse)
• Mylan NV (États-Unis)
• Teva Pharmaceutical Industries Ltd (Israël)
• Groupe Zydus (Inde)
• Pfizer Inc (États-Unis)
• Lupin (Inde)
• GSK Plc (Royaume-Uni)
• Glenmark Pharmaceuticals Inc (Inde)
• Amneal Pharmaceuticals (États-Unis)
• Alnylam Pharmaceuticals, Inc (États-Unis)
• DAIICHI SANKYO COMPANY, LIMITED (Japon)

SKU-54518